Trump Orders FDA Review of Breakthrough Psychedelic Therapies

President Donald Trump signed an executive order on Saturday aimed at accelerating the review process for psychedelic drugs that have shown promise in treating mental health conditions, particularly among veterans struggling with depression and other psychological disorders.

The order specifically instructs the Food and Drug Administration to expedite reviews of psychedelic compounds that have already received breakthrough therapy designation, a classification that speeds up the development and review of drugs intended to treat serious conditions.

“In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans,” Trump said during the signing ceremony at the White House. He specifically highlighted the high suicide rate among veterans as a key motivation behind the initiative.

The executive order represents a significant shift in federal policy toward substances that have long been classified as Schedule I drugs with “no currently accepted medical use.” Several psychedelic compounds, including psilocybin (found in “magic mushrooms”) and MDMA, have received breakthrough therapy designations from the FDA in recent years for conditions such as treatment-resistant depression and post-traumatic stress disorder.

Mental health advocates have praised the development as potentially transformative for patients who haven’t responded to conventional treatments. The research into psychedelics has gained momentum over the past decade, with respected medical institutions including Johns Hopkins University, New York University, and the University of California, Berkeley establishing dedicated research centers to study their therapeutic potential.

The move comes amid growing bipartisan interest in psychedelic therapy. Several states and municipalities have already moved to decriminalize or legalize certain psychedelic substances for therapeutic or personal use. Oregon became the first state to legalize psilocybin therapy in 2020, while Colorado followed with a similar measure in 2022.

The pharmaceutical industry has also taken note of this emerging field. Companies like Compass Pathways, MindMed, and Atai Life Sciences have attracted significant investment to develop psychedelic-assisted therapies through FDA-approved channels. Market analysts project the psychedelic medicine market could reach billions of dollars within the next decade if these treatments receive full FDA approval.

Veterans’ organizations have been among the most vocal advocates for psychedelic research, with many former service members reporting dramatic improvements in PTSD symptoms after supervised psychedelic therapy sessions. The Department of Veterans Affairs has begun limited research into these treatments, though regulatory hurdles have slowed widespread clinical trials.

The executive order specifically addresses compounds currently in “advanced stages of clinical trials,” suggesting that treatments could potentially become available to patients within the next few years if they meet safety and efficacy standards. This accelerated timeline could bring relief to patients who have exhausted conventional treatment options.

Critics of the order have expressed concerns about potential misuse of these powerful compounds and questioned whether expediting the review process might compromise safety standards. However, proponents note that the FDA’s breakthrough therapy program maintains rigorous scientific standards while eliminating unnecessary bureaucratic delays.

The administration emphasized that the order doesn’t change the legal status of these substances for recreational use but rather creates a more efficient pathway for developing them as controlled medications administered by healthcare professionals in appropriate settings.

This policy shift reflects a growing recognition in the medical community that certain controlled substances, despite their controversial history, may offer significant therapeutic benefits when used under proper medical supervision. Clinical trials have shown particular promise for conditions that have proven resistant to conventional pharmaceutical approaches.

The executive order marks another example of the evolving approach to drug policy in the United States, where scientific evidence is increasingly shaping regulatory decisions around substances that were previously dismissed for their potential for misuse rather than evaluated for their therapeutic value.